Barry Singer, ECTRIMS 2022: Flushing and GI adverse events in RRMS patients on diroximel fumarate – Analysis from phase 3 EVOLVE-MS-1 study

The phase 3 EVOLVE-MS-1 (NCT02634307), was a 96-week, open-label, Phase 3 study, assessing safety, tolerability, and exploratory clinical and MRI efficacy of diroximel fumarate in adults with relapsing-remitting multiple sclerosis (RRMS). Diroximel fumarate, an oral fumarate for relapsing-remitting multiple sclerosis, has the same active metabolite, and similar efficacy and safety to dimethyl fumarate but with improved gastrointestinal tolerability. In this touchNEUROLOGY interview, we caught up with Dr Barry Singer (Missouri Baptist Medical Center, St Louis, USA) to discuss the flushing and gastrointestinal (GI) adverse events analysis from the phase 3 EVOLVE-MS-1 study. As flushing and GI adverse events are common for patients on dimethyl fumarate, the analysis found that diroximel fumarate has similar safety and efficacy to dimethyl fumarate but with improved GI tolerability.

The abstract entitled ‘Flushing and gastrointestinal adverse event analysis from the phase 3 EVOLVE-MS-1 study of diroximel fumarate in patients with relapsing-remitting multiple sclerosis’ (Abstract #P735) was presented at ECTRIMS, 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, 26 – 28 October 2022, Amsterdam, the Netherlands.

Questions:

1. What are the potential advantages of diroximel fumarate over dimethyl fumarate? (0:16)
2. What were the findings from the flushing and gastrointestinal adverse events analysis from the phase 3 EVOLVE-MS-1 study? (1:18)

Disclosures: Barry Singer is a consultant for AbbVie, Biogen, EMD Serono, Janssen, Genentech, Greenwich Biosciences, Novartis, Octave Bioscience, Roche, Sanofi and TG Therapeutics; receives grant/research support from AbbVie, Biogen, Bristol Myers Squibb, Greenwich Biosciences, Novartis and Sanofi; and is on the advisory board for Cigna; receives Honoraria/Honorarium from AbbVie, Alexion, Biogen, Bristol Myers Squibb, Cigna, EMD Serono, Janssen, Genentech, Greenwich Biosciences, Horizon, Novartis, Octave Bioscience, Roche, Sanofi and TG Therapeutics; and is a speaker’s bureau participant with Alexion, Biogen, Bristol Myers Squibb, EMD Serono, Janssen, Genentech, Horizon, Novartis, Roche, Sanofi and TG Therapeutics.

Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.

Filmed as a highlight of ECTRIMS 2022

Access more content on MS here